Dr. David Palma, MD
Claim this profileLondon Health Sciences Centre
Studies Cancer
Studies Head and Neck Cancers
10 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials David Palma, MD is currently running
SABR
for Oligometastatic Cancer
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) alone, on overall survival, progression-free survival, toxicity, and quality of life. An integrated economic evaluation will determine the cost per quality of life year gained using SABR (vs. SOC) and a translational component will enable identification of predictive/prognostic biomarkers of the oligometastatic state.
Recruiting1 award N/A19 criteria
Vocal-cord vs. Complete Larynx Radiotherapy
for Early Glottic Cancer
This is a multicentrer, randomized Bayesian Phase II trial for patients with early stage (T1N0) glottic squamous cell carcinoma treated with radical radiotherapy. The primary objective is to assess the non-inferiority of local control achieved with vocal-cord only radiotherapy (VC-RT) compared to complete larynx radiotherapy (CL-RT) in T1N0 glottic laryngeal squamous cell cancer, measured at 2-years after treatment. Secondary outcomes include overall survival, as well as voice impairment, dysphagia and quality of life, measured respectively by the voice handicap index -10 (VHI-10), the MD Anderson Dysphagia Inventory (MDADI) and the MD Anderson Symptom Inventory- Head and Neck module (MDASI-HN). Patients will be randomized in a 1:3 ratio to CL-RT (39 patients) and VC-RT (116 patients) arms. There will be stratification by tumor stage (T1a/T1b) and by institution. An interim analysis is planned after the first 55 patients enrolled on the experimental arm have a 6-month follow-up.
Recruiting1 award Phase 25 criteria
More about David Palma, MD
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments David Palma, MD has experience with
- Stereotactic Ablative Radiotherapy
- PRO-ACTIVE EAT + EXERCISE
- PRO-ACTIVE EAT
- RE-ACTIVE
- Opioids
- PAiN - Multimodal Analgesia
Breakdown of trials David Palma, MD has run
Cancer
Head and Neck Cancers
Lung Disease
Interstitial Lung Disease
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Palma, MD specialize in?
David Palma, MD focuses on Cancer and Head and Neck Cancers. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is David Palma, MD currently recruiting for clinical trials?
Yes, David Palma, MD is currently recruiting for 3 clinical trials in London Ontario. If you're interested in participating, you should apply.
Are there any treatments that David Palma, MD has studied deeply?
Yes, David Palma, MD has studied treatments such as Stereotactic Ablative Radiotherapy, PRO-ACTIVE EAT + EXERCISE, PRO-ACTIVE EAT.
What is the best way to schedule an appointment with David Palma, MD?
Apply for one of the trials that David Palma, MD is conducting.
What is the office address of David Palma, MD?
The office of David Palma, MD is located at: London Health Sciences Centre, London, Ontario N6A 5W9 Canada. This is the address for their practice at the London Health Sciences Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.